Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 13 recruiting now early-phase tilt

Diabetic Kidney Disease: early-phase trial registry

13 of 24 indexed Diabetic Kidney Disease trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #686 of 28,707 conditions by registered trial count.

24 US clinical trials · 13 currently recruiting · #686 of 28,707 conditions by registered trial count

Diabetic Kidney Disease: 24 US clinical trials tracked, 13 recruiting.

Diabetic Kidney Disease is the subject of 24 registered US clinical trials on ClinicalTrials.gov, 13 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 12 in Phase 1-2 (earlier-stage). The most active sponsor is University of Colorado, Denver, running 6 of these trials.

Enrollment posture brief

Registry condition diabetic-kidney-disease

OPEN 13 | RECR 54% | LATE 3 | EARLY 12 | RANK #686 | SPON 6

Nearest open-share peer: Bulimia Nervosa (54% recruiting · 24 trials)

Diabetic Kidney Disease (thi…54%Aplastic Anemia37.5%Behavior37.5%Allergic Rhinitis8.3%Adult Acute Myeloid Leukemia0%
Open-enrollment share among volume-matched conditions near Diabetic Kidney Disease

Diabetic Kidney Disease lists 13 open slots (54% of 24 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Diabetic Kidney Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Diabetic Kidney Disease is recruiting above its size-band peers.

    13 of 24 indexed trials (54.2%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Diabetic Kidney Disease research.

    University of Colorado, Denver accounts for 6 of 24 trials (25%). 15 distinct sponsors appear on at least one study for this condition label.

  3. Typical Diabetic Kidney Disease enrolment sits around 103 participants.

    Median target enrolment is 103 among the 24 trials that report a genuine target (sentinel values excluded). 10 of those (41.7%) plan for fewer than 100 participants.

  4. Diabetic Kidney Disease splits between interventional and observational designs.

    15 interventional and 9 observational studies make up this index (62.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 13Phase 29Phase 43

Open and recent trials

24 total, page 1 of 1

RECRUITING 100,000 participants

Family Investigation of Nephropathy and Diabetes (F.I.N.D.)

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NCT00342927

RECRUITING 10,000 participants

Real World Evidence Clinical Utility Study of KidneyIntelX

Renalytix AI

NCT04802395

RECRUITING 1,500 participants

Decision Impact Trial of KidneyIntelX

Renalytix AI

NCT04791358

RECRUITING Phase 2 140 participants

NAD Augmentation in Diabetes Kidney Disease

Brigham and Women's Hospital

NCT05759468

RECRUITING Phase 2 120 participants

Formoterol in Diabetes

Medical University of South Carolina

NCT07022418

RECRUITING Phase 1 120 participants

Dosimetry of Tc-99m-Tilmanocept

University of California, San Diego

NCT05241522

RECRUITING 100 participants

Pathogenesis of Kidney Disease in Type 1 Diabetes: a Modern Kidney Biopsy Cohort (The PANDA Study)

University of Colorado, Denver

NCT05319990

RECRUITING 100 participants

Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)

Petter Bjornstad

NCT05008276

RECRUITING 80 participants

A Long-Term Follow-Up Study of Participants Exposed to REACT

Prokidney

NCT05918523

RECRUITING Phase 1 60 participants

MANATEE-T1D: Metformin ANd AutomaTEd Insulin Delivery System Effects on Renal Vascular Resistance, Insulin Sensitivity, and Cardiometabolic Function in Youth With Type 1 Diabetes

Kalie Tommerdahl

NCT05065372

RECRUITING Phase 2 60 participants

Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes

University of Washington

NCT05822609

RECRUITING Phase 2 40 participants

Renal Mechanism of SGLT2 Inhibition

University of Colorado, Denver

NCT05507892

RECRUITING Phase 4 20 participants

Mechanism of SGLT2 Inhibition in the Kidney

University of Michigan

NCT06291155

ACTIVE NOT RECRUITING Phase 4 2,376 participants

Pentoxifylline in Diabetic Kidney Disease

VA Office of Research and Development

NCT03625648

ACTIVE NOT RECRUITING 2,000 participants

Prospective Decision Impact Trial of KidneyIntelX

Renalytix AI

NCT04960514

ACTIVE NOT RECRUITING 2,000 participants

Prospective Decision Impact Clinical Utility Trial of KidneyIntelX

Renalytix AI

NCT05198284

ACTIVE NOT RECRUITING Phase 2 103 participants

Atrasentan in Patients With Proteinuric Glomerular Diseases

Novartis Pharmaceuticals

NCT04573920

ACTIVE NOT RECRUITING 50 participants

MEtabolic and Renal Effects of AutoMAted Insulin Delivery Systems in Youth With Type 1 Diabetes Mellitus

University of Colorado, Denver

NCT03945747

COMPLETED Phase 2 265 participants

Phase 2 Study of INV-202 in Patients With Diabetic Kidney Disease

Inversago Pharma

NCT05514548

COMPLETED Phase 2 130 participants

A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease

Eli Lilly and Company

NCT01683409

COMPLETED Phase 4 45 participants

Effect of Urinary Alkalinization on Urine Uric Acid Precipitation and Crystallization in Adults With Type 1 Diabetes

University of Colorado, Denver

NCT02502071

COMPLETED Phase 1 24 participants

Impact of Metabolic Surgery on Pancreatic, Renal and Cardiovascular Health in Youth With Type 2 Diabetes

University of Colorado, Denver

NCT03620773

COMPLETED Phase 2 22 participants

Randomized Controlled Trial of Vitamin D3 in Diabetic Kidney Disease

University of Washington

NCT00552409

COMPLETED Phase 2 10 participants

Evaluation of Coffee Therapy for Improvement of Renal Oxygenation

University of Colorado, Denver

NCT03878277

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 9
Phase 4 3

Named interventions

Most-linked intervention names on Diabetic Kidney Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
5 trials
KidneyIntelX Diagnostic test
4 trials
Aminohippurate Sodium Inj 20% Drug
3 trials
INV-202 Drug
1 trials
sodium bicarbonate Drug
1 trials
Iohexol Inj 300 mg/mL Drug
1 trials
Renal Biopsy Procedure
1 trials
Starbucks® Cold brew - 325ml bottle Drug
1 trials

US sites by state

Facility locations filed on Diabetic Kidney Disease trials. A trial with sites in several states counts in each.

Colorado 12 trials
California 5 trials
Washington 4 trials
Michigan 4 trials
New York 3 trials
North Carolina 3 trials
Missouri 3 trials
Illinois 3 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Diabetic Kidney Disease page

24 registered trials, 13 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Diabetic Kidney Disease condition card totals 24 registered trials; most-linked intervention Placebo; top US site state Colorado. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.